DMD

Norcross Complete Dentistry is Opening Doors to Patients, Providing Exceptional Dental Care with a Personal Touch

Retrieved on: 
Mercredi, mai 1, 2024
Oral medicine, University, Patient, Dental care, Dentistry, OKU, University of Illinois Urbana-Champaign, Communication, Trust, DMD, Environment, Family, Professional, American Dental Association, Multimedia, Health, Omicron Kappa Upsilon

PEACHTREE CORNERS, Ga, May 1, 2024 /PRNewswire-PRWeb/ -- Norcross Complete Dentistry is thrilled to announce the grand opening of their office on May 1st, 2024. At Norcross Complete Dentistry, they believe in the power of personalized experiences with the goal of creating a warm and welcoming environment where patients feel at ease. The team is committed to delivering exceptional service and outstanding results, ensuring that every patient leaves the office with a healthy and confident smile. The clinic delivers a broad spectrum of dental care that ensures maximum comfort, including general, cosmetic, restorative and emergency dentistry, along with specialized pediatric dental services for younger patients. Utilizing the latest in dental technology, the team offers efficient, precise and innovative treatments, including 3D cone beam imaging, TRIOS 3Shape® and iTero Intraoral scanners. By combining cutting-edge technology with a compassionate approach, the practice aims to exceed patient expectations and provide the highest quality of care. Trust and transparency are key at Norcross Complete Dentistry, and the clinic offers clear communication about treatment plans and pricing, ensuring no surprises for valued patients. The practice accepts a diverse range of dental insurance plans from numerous companies, making it easier for patients to receive the dental care they need without financial strain.

Key Points: 
  • PEACHTREE CORNERS, Ga, May 1, 2024 /PRNewswire-PRWeb/ -- Norcross Complete Dentistry is thrilled to announce the grand opening of their office on May 1st, 2024.
  • The clinic delivers a broad spectrum of dental care that ensures maximum comfort, including general, cosmetic, restorative and emergency dentistry , along with specialized pediatric dental services for younger patients.
  • More about Norcross Complete Dentistry:
    Known for unmatched patient care, Norcross Complete Dentistry is a top-rated dental practice in Peachtree Corners, dedicated to fulfilling all types of dental needs.
  • Dr. Kavuri focuses on comprehensive dental care for the entire family and strives to provide quality dental care for adults and children.

Grand Opening of Affordable Dentures & Implants in Ross Township, Pennsylvania Enhances Patient Access to Quality, Affordable Dental Care

Retrieved on: 
Mercredi, mai 1, 2024
Dental implant, Patient, DMD, Dentures, DDS, Dentistry

ROSS TOWNSHIP, Pa., May 1, 2024 /PRNewswire/ -- The new Affordable Dentures & Implants practice in Ross Township, Pennsylvania, located at 7219 McKnight Road, Suite D, is now open. The practice joins the nation's largest provider network of dental practices – supported by Affordable Care – that provide tooth replacement services. 

Key Points: 
  • ROSS TOWNSHIP, Pa., May 1, 2024 /PRNewswire/ -- The new Affordable Dentures & Implants practice in Ross Township, Pennsylvania , located at 7219 McKnight Road, Suite D, is now open.
  • The practice joins the nation's largest provider network of dental practices – supported by Affordable Care – that provide tooth replacement services.
  • From extractions and partial dentures to full dentures and dental implants , including implant-secured dentures , Affordable Dentures & Implants in Ross Township offers quality, affordable tooth replacement care.
  • Practice Owner Olajumoke Adedoyin, DDS, General Dentist, Managing Dentist Andy Shieh, DMD, General Dentist, and the Affordable Dentures & Implants team in Ross Township are proud to offer professional and compassionate care to patients.

Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on: 
Jeudi, mai 2, 2024
Sale, American Academy, Episcopal conference, MDA, Research, Muscular Dystrophy Association, DMD, Conference, Therapy, DYN, DM1, G&A, Pharmaceutical industry

WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the first quarter of 2024 and recent business highlights.

Key Points: 
  • (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the first quarter of 2024 and recent business highlights.
  • Research and development (R&D) expenses: R&D expenses were $44.5 million for the quarter ended March 31, 2024, compared to $37.5 million for the quarter ended March 31, 2023.
  • General and administrative (G&A) expenses: G&A expenses were $24.6 million for the quarter ended March 31, 2024, compared to $7.9 million for the quarter ended March 31, 2023.
  • Net loss: Net loss for the quarter ended March 31, 2024 was $65.6 million, or $0.81 per basic and diluted share.

Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May

Retrieved on: 
Jeudi, avril 25, 2024
FDA, Annual, Pharmacy, NMPA, Private, Partnership, CDE, PDUFA, CEPS, European Medicines Agency, News, Annual report, Intangibles, DMD, U.S. FDA, Catalyst Pharmaceuticals, Tax, CHF, MHRA, Duchenne muscular dystrophy, Quality of life, Leber's hereditary optic neuropathy, Vamorolone, BST, Public, EMA, Marketing, File, Sale, Medication, Treasury, NDA, Health care, Duchenne, Bond, Patient, Bank statement, AGM, Growth, Cryptocurrency

As permitted by SIX Exchange Regulation, the Company will publish the full 2023 Annual Report in May.

Key Points: 
  • As permitted by SIX Exchange Regulation, the Company will publish the full 2023 Annual Report in May.
  • Financially, Santhera reported a 2023 revenue of CHF 103.4 million and net income of CHF 54.8 million, driven by the Catalyst licensing deal.
  • After closing of the transaction in July 2023, Santhera received an upfront payment of USD 90 million (USD 75 million in cash and USD 15 million equity investment).
  • SIX Exchange Regulation has permitted Santhera to publish its 2023 Annual Report by May 31, 2024, at the latest.

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy

Retrieved on: 
Mercredi, avril 24, 2024
FDA, PRV, Safety, Regenerative medicine, Food, Orphan, DMD, Webcast, Biologics license application, Therapy, Priority review, Exosome, BLA, Duchenne muscular dystrophy, Marketing, ID, File, Biotechnology, Pharmaceutical industry

SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, today announced an update from the Company’s recent Type-B Chemistry, Manufacturing and Controls (“CMC”) meeting with the U.S. Food and Drug Administration (“FDA”) on next steps for the Biologics License Application (“BLA”) submission with its lead asset CAP-1002 in treating Duchenne muscular dystrophy (“DMD”).

Key Points: 
  • The FDA has affirmed alignment with Capricor on the following topics:
    The FDA advised Capricor to include discussion for a pre-BLA meeting and rolling BLA schedule in the upcoming Type-B meeting.
  • This allows for the use of CAP-1002 drug product manufactured at our San Diego manufacturing facility upon potential product approval.
  • Data from Cohort B of the HOPE-3 clinical trial will not be necessary for FDA approval of the product.
  • Contingent upon our upcoming meeting, FDA is supportive of our plan to submit a rolling BLA, which may expedite our path to potential approval.

Revolutionary Scientists Honored for Advancements in Gene Therapy for Neuromuscular Diseases and RNA Discoveries: King Faisal Prize Laureates in Medicine, Professor Jerry Mendell, and in Science, Professor Howard Chang, Awarded

Retrieved on: 
Lundi, avril 22, 2024
Science (journal), Mortality, FDA, Pediatric Research, Protein, Chromatin, Cell, Limb–girdle muscular dystrophy, Research, American Philosophical Society, National Cancer Institute, Molecular biology, Life, Gene, Quran, Food, LGMD, SMA, RNA, DMD, Spinal muscular atrophy, Infant, Dystrophin, Nationwide, Duchenne muscular dystrophy, Ageing, National academy, Hospital, Cancer research, Literature, DNA, Therapy, Gene expression, Muscular dystrophy, Chromosome, USD, Stanford University, Cancer, Islamic studies, Muscle weakness, Disease, Vilcek Foundation, Patient, Assay, Society, Listeria monocytogenes non-coding RNA, Pharmaceutical industry

Genetic mutations in Duchenne muscular dystrophy (DMD) patients hinder the production of dystrophin, a crucial protein for muscle health.

Key Points: 
  • Genetic mutations in Duchenne muscular dystrophy (DMD) patients hinder the production of dystrophin, a crucial protein for muscle health.
  • Gene therapy offers a solution by addressing this genetic anomaly, allowing the body to produce dystrophin and halt muscle degeneration.
  • Ludwig Professor of Cancer Research at Stanford University, has been awarded King Faisal Prize for Science in Biology.
  • Since 1979, King Faisal Prize in its 5 different categories has awarded 295 laureates who have made distinguished contributions to different sciences and causes.

TeleRare Health™ Announces Launch of National Virtual Clinic for Rare Disease Patients

Retrieved on: 
Mardi, avril 30, 2024
Wilson's disease, Bangladesh Technical Education Board, Genomics, Kidney, SCID, Diagnosis, Safety, NIH, AI, Heart, Adrenoleukodystrophy, MD, Partnership, Children's National Hospital, DMD, FXS, Research, Human, Genetic testing, Disease, Patient, ALD, Pediatrics, Krabbe disease, Duchenne muscular dystrophy, PD, GMG, Fragile X syndrome, Pharmaceutical industry

MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- 8:00a (CET) April 30, 2024 - TeleRare Health™ launched today, a virtual clinic for Rare Disease patients and their families.

Key Points: 
  • MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- 8:00a (CET) April 30, 2024 - TeleRare Health™ launched today, a virtual clinic for Rare Disease patients and their families.
  • TeleRare Health aims to be the premier provider of virtual care for rare and genomic disease nationwide, envisioning a world where all patients have access to cutting edge diagnostics, treatments, and specialists.
  • "Significant breakthroughs have occurred in the management of rare disease," said Alex Katz, MD, medical geneticist and Chief Medical Officer of TeleRare Health.
  • We're overdue for a virtual clinic for the millions of Americans with rare disease conditions, and TeleRare Health's launch is cause for optimism.

Tula Technology to Demonstrate Dynamic Motor Drive® (DMD) at Vienna Motor Symposium

Retrieved on: 
Mardi, avril 16, 2024
Automotive, Other Science, Technology, Engineering, Sustainability, Automotive Manufacturing, Manufacturing, Environment, Public Transport, Other Transport, Batteries, Green Technology, Alternative Energy, Energy, Transport, Performance & Special Interest, Software, EV, Electric Vehicles, Alternative Vehicles, Fuels, Science, DMD, Chevrolet Bolt, Bolt, Tesla Model 3, Vibration, PMSM, Multimedia, Electric motor

Tula Technology, Inc. , a leader in propulsion efficiency, will put its Dynamic Motor Drive® (DMD) technology into action at the 45th International Vienna Motor Symposium on April 24-26 in Vienna, Austria.

Key Points: 
  • Tula Technology, Inc. , a leader in propulsion efficiency, will put its Dynamic Motor Drive® (DMD) technology into action at the 45th International Vienna Motor Symposium on April 24-26 in Vienna, Austria.
  • View the full release here: https://www.businesswire.com/news/home/20240416986692/en/
    Tula has retrofitted a Tesla Model 3 with an externally excited synchronous motor (EESM) running Dynamic Motor Drive® software.
  • This innovative technology will be demonstrated at the 45th International Vienna Motor Symposium on April 24-26 in Vienna, Austria.
  • Members of Tula’s DMD development team will present a paper on their DMD findings at the Vienna Motor Symposium.

Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics

Retrieved on: 
Mardi, avril 16, 2024
Technology, Biotechnology, FDA, Nanotechnology, Health, Pharmaceutical, Stem Cells, Other Science, Research, Infectious Diseases, Genetics, Fitness & Nutrition, Science, Clinical Trials, CTA, CRISPR, PMM, OTC, Gene editing, Partnership, Doctor of Philosophy, DMD, Prevail, Webcast, IND, Entrepreneurship, Novartis, DNA, Precision BioSciences, GLP, Eli Lilly and Company, CTAS, Toxicology, ID, Therapy, Precision, HBV, Vaccine

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company.
  • Precision exercised its option to regain rights for the programs following Prevail Therapeutics’ decision to conclude the collaboration.
  • The collaboration began in January 2021 and was amended in June 2023 to transfer certain preclinical research, manufacturing, and investigational new drug (IND)-enabling activities from Precision BioSciences to Prevail Therapeutics.
  • “We enjoyed a productive gene editing collaboration with Prevail Therapeutics and appreciate their contributions to the success of these programs.

Duchenne UK and Parent Project Muscular Dystrophy Award $500,000 to Evaluate Safety and Tolerability of Muscle Progenitor Cells in Phase 1 Trial

Retrieved on: 
Mardi, avril 23, 2024
University, Cell, Hope, Safety, DMD, Research, Dystrophin, Entrepreneurship, Patient, PPMD, Translational medicine, Duchenne muscular dystrophy, Clinical trial, Therapy, Organization, Injection, CGMP, Pharmaceutical industry

The grant, totaling $500,000, will support Dr. Kang and his co-investigators in evaluating the safety and tolerability of muscle progenitor cells for Duchenne muscular dystrophy.

Key Points: 
  • The grant, totaling $500,000, will support Dr. Kang and his co-investigators in evaluating the safety and tolerability of muscle progenitor cells for Duchenne muscular dystrophy.
  • Dr. Kang's project builds on previous research, utilizing muscle progenitor cells, known as MyoPAXon, developed by Dr. Rita Perlingeiro and her team at the University of Minnesota.
  • This Phase 1 trial led by Dr. Kang's team will provide valuable insights into the safety and feasibility of transplanting MyoPAXon cells.
  • Emily Reuben, Co-Founder and CEO of Duchenne UK, explains:
    "Duchenne UK has supported Dr. Perlingeiro's work on developing muscle progenitor cells for a number of years.